Clin Microbiol Infect:疫苗对异源适应性免疫的影响

2020-06-14 MedSci原创 MedSci原创

疫苗能诱导适应性免疫细胞的抗原特异性记忆,从而实现对目标病原体的长效保护。除此之外,一些疫苗的有益效果大于对目标病原体的保护。这些非特异性效应被认为是疫苗诱导的免疫调节的结果。在卡介苗(BCG)的情况

疫苗能诱导适应性免疫细胞的抗原特异性记忆,从而实现对目标病原体的长效保护。除此之外,一些疫苗的有益效果大于对目标病原体的保护。这些非特异性效应被认为是疫苗诱导的免疫调节的结果。在卡介苗(BCG)的情况下,这涉及诱导单核细胞和自然杀伤细胞的先天免疫记忆,即 "训练免疫"。本文讨论了目前疫苗诱导的适应性免疫细胞和异源适应性免疫反应的免疫调节证据。

 

与婴儿全因死亡率变化有关的三种疫苗。卡介苗、白喉-破伤风-百日咳(DTP)和含麻疹疫苗(MCV)会改变T细胞和B细胞免疫。大多数调查这些疫苗对适应性免疫系统的非特异性影响的研究报告了适应性免疫细胞群数量或比例的变化。然而,也有证据表明这些疫苗对适应性免疫细胞功能和对异源刺激的反应产生了影响。有一些证据表明,除了卡介苗、DTP和MCV,其他疫苗(与全因死亡率的变化无关)可能会改变对不相关刺激的适应性免疫反应。

 

总之,疫苗会改变适应性免疫细胞群和异源性免疫反应。各种疫苗的非特异性效应不同,其对异源适应性免疫反应的影响也可能涉及旁观者激活、交叉反应和其他尚未定义的机制。这对今后的疫苗设计和疫苗接种安排有重大影响。

 

原始出处:

 

N L Messina, P Zimmermann, N Curtis. The Impact of Vaccines on Heterologous Adaptive Immunity. Clin Microbiol Infect. 2019 Dec;25(12):1484-1493. doi: 10.1016/j.cmi.2019.02.016.

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (6)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=2084591, encodeId=f6f220845912b, content=<a href='/topic/show?id=61f411e013b' target=_blank style='color:#2F92EE;'>#Micro#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=19, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11701, encryptionId=61f411e013b, topicName=Micro)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d59291, createdName=xjy02, createdTime=Thu Aug 06 22:11:22 CST 2020, time=2020-08-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1814228, encodeId=f6971814228d5, content=<a href='/topic/show?id=0c4094e0431' target=_blank style='color:#2F92EE;'>#适应性免疫#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94704, encryptionId=0c4094e0431, topicName=适应性免疫)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1376173, createdName=linagood, createdTime=Tue Mar 30 23:11:22 CST 2021, time=2021-03-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1767768, encodeId=ff501e6776815, content=<a href='/topic/show?id=64f5343e2f' target=_blank style='color:#2F92EE;'>#Biol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3437, encryptionId=64f5343e2f, topicName=Biol)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=446937890434, createdName=12498ebem31暂无昵称, createdTime=Thu Apr 29 17:11:22 CST 2021, time=2021-04-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1919083, encodeId=9f02191908378, content=<a href='/topic/show?id=4f26341994' target=_blank style='color:#2F92EE;'>#Bio#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=19, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3419, encryptionId=4f26341994, topicName=Bio)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12de429, createdName=sunylz, createdTime=Mon Mar 29 19:11:22 CST 2021, time=2021-03-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1857888, encodeId=8ce1185e8880a, content=<a href='/topic/show?id=3f48525849' target=_blank style='color:#2F92EE;'>#CRO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5258, encryptionId=3f48525849, topicName=CRO)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c30265, createdName=jiafufeng@yaho, createdTime=Wed Feb 17 17:11:22 CST 2021, time=2021-02-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1621037, encodeId=74a3162103ec8, content=<a href='/topic/show?id=dccc94e01c9' target=_blank style='color:#2F92EE;'>#适应性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94701, encryptionId=dccc94e01c9, topicName=适应性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b13a20191510, createdName=huhuaidong394, createdTime=Tue Jun 16 09:11:22 CST 2020, time=2020-06-16, status=1, ipAttribution=)]
    2020-08-06 xjy02
  2. [GetPortalCommentsPageByObjectIdResponse(id=2084591, encodeId=f6f220845912b, content=<a href='/topic/show?id=61f411e013b' target=_blank style='color:#2F92EE;'>#Micro#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=19, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11701, encryptionId=61f411e013b, topicName=Micro)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d59291, createdName=xjy02, createdTime=Thu Aug 06 22:11:22 CST 2020, time=2020-08-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1814228, encodeId=f6971814228d5, content=<a href='/topic/show?id=0c4094e0431' target=_blank style='color:#2F92EE;'>#适应性免疫#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94704, encryptionId=0c4094e0431, topicName=适应性免疫)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1376173, createdName=linagood, createdTime=Tue Mar 30 23:11:22 CST 2021, time=2021-03-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1767768, encodeId=ff501e6776815, content=<a href='/topic/show?id=64f5343e2f' target=_blank style='color:#2F92EE;'>#Biol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3437, encryptionId=64f5343e2f, topicName=Biol)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=446937890434, createdName=12498ebem31暂无昵称, createdTime=Thu Apr 29 17:11:22 CST 2021, time=2021-04-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1919083, encodeId=9f02191908378, content=<a href='/topic/show?id=4f26341994' target=_blank style='color:#2F92EE;'>#Bio#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=19, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3419, encryptionId=4f26341994, topicName=Bio)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12de429, createdName=sunylz, createdTime=Mon Mar 29 19:11:22 CST 2021, time=2021-03-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1857888, encodeId=8ce1185e8880a, content=<a href='/topic/show?id=3f48525849' target=_blank style='color:#2F92EE;'>#CRO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5258, encryptionId=3f48525849, topicName=CRO)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c30265, createdName=jiafufeng@yaho, createdTime=Wed Feb 17 17:11:22 CST 2021, time=2021-02-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1621037, encodeId=74a3162103ec8, content=<a href='/topic/show?id=dccc94e01c9' target=_blank style='color:#2F92EE;'>#适应性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94701, encryptionId=dccc94e01c9, topicName=适应性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b13a20191510, createdName=huhuaidong394, createdTime=Tue Jun 16 09:11:22 CST 2020, time=2020-06-16, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=2084591, encodeId=f6f220845912b, content=<a href='/topic/show?id=61f411e013b' target=_blank style='color:#2F92EE;'>#Micro#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=19, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11701, encryptionId=61f411e013b, topicName=Micro)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d59291, createdName=xjy02, createdTime=Thu Aug 06 22:11:22 CST 2020, time=2020-08-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1814228, encodeId=f6971814228d5, content=<a href='/topic/show?id=0c4094e0431' target=_blank style='color:#2F92EE;'>#适应性免疫#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94704, encryptionId=0c4094e0431, topicName=适应性免疫)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1376173, createdName=linagood, createdTime=Tue Mar 30 23:11:22 CST 2021, time=2021-03-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1767768, encodeId=ff501e6776815, content=<a href='/topic/show?id=64f5343e2f' target=_blank style='color:#2F92EE;'>#Biol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3437, encryptionId=64f5343e2f, topicName=Biol)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=446937890434, createdName=12498ebem31暂无昵称, createdTime=Thu Apr 29 17:11:22 CST 2021, time=2021-04-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1919083, encodeId=9f02191908378, content=<a href='/topic/show?id=4f26341994' target=_blank style='color:#2F92EE;'>#Bio#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=19, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3419, encryptionId=4f26341994, topicName=Bio)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12de429, createdName=sunylz, createdTime=Mon Mar 29 19:11:22 CST 2021, time=2021-03-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1857888, encodeId=8ce1185e8880a, content=<a href='/topic/show?id=3f48525849' target=_blank style='color:#2F92EE;'>#CRO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5258, encryptionId=3f48525849, topicName=CRO)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c30265, createdName=jiafufeng@yaho, createdTime=Wed Feb 17 17:11:22 CST 2021, time=2021-02-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1621037, encodeId=74a3162103ec8, content=<a href='/topic/show?id=dccc94e01c9' target=_blank style='color:#2F92EE;'>#适应性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94701, encryptionId=dccc94e01c9, topicName=适应性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b13a20191510, createdName=huhuaidong394, createdTime=Tue Jun 16 09:11:22 CST 2020, time=2020-06-16, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=2084591, encodeId=f6f220845912b, content=<a href='/topic/show?id=61f411e013b' target=_blank style='color:#2F92EE;'>#Micro#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=19, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11701, encryptionId=61f411e013b, topicName=Micro)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d59291, createdName=xjy02, createdTime=Thu Aug 06 22:11:22 CST 2020, time=2020-08-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1814228, encodeId=f6971814228d5, content=<a href='/topic/show?id=0c4094e0431' target=_blank style='color:#2F92EE;'>#适应性免疫#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94704, encryptionId=0c4094e0431, topicName=适应性免疫)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1376173, createdName=linagood, createdTime=Tue Mar 30 23:11:22 CST 2021, time=2021-03-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1767768, encodeId=ff501e6776815, content=<a href='/topic/show?id=64f5343e2f' target=_blank style='color:#2F92EE;'>#Biol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3437, encryptionId=64f5343e2f, topicName=Biol)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=446937890434, createdName=12498ebem31暂无昵称, createdTime=Thu Apr 29 17:11:22 CST 2021, time=2021-04-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1919083, encodeId=9f02191908378, content=<a href='/topic/show?id=4f26341994' target=_blank style='color:#2F92EE;'>#Bio#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=19, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3419, encryptionId=4f26341994, topicName=Bio)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12de429, createdName=sunylz, createdTime=Mon Mar 29 19:11:22 CST 2021, time=2021-03-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1857888, encodeId=8ce1185e8880a, content=<a href='/topic/show?id=3f48525849' target=_blank style='color:#2F92EE;'>#CRO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5258, encryptionId=3f48525849, topicName=CRO)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c30265, createdName=jiafufeng@yaho, createdTime=Wed Feb 17 17:11:22 CST 2021, time=2021-02-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1621037, encodeId=74a3162103ec8, content=<a href='/topic/show?id=dccc94e01c9' target=_blank style='color:#2F92EE;'>#适应性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94701, encryptionId=dccc94e01c9, topicName=适应性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b13a20191510, createdName=huhuaidong394, createdTime=Tue Jun 16 09:11:22 CST 2020, time=2020-06-16, status=1, ipAttribution=)]
    2021-03-29 sunylz
  5. [GetPortalCommentsPageByObjectIdResponse(id=2084591, encodeId=f6f220845912b, content=<a href='/topic/show?id=61f411e013b' target=_blank style='color:#2F92EE;'>#Micro#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=19, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11701, encryptionId=61f411e013b, topicName=Micro)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d59291, createdName=xjy02, createdTime=Thu Aug 06 22:11:22 CST 2020, time=2020-08-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1814228, encodeId=f6971814228d5, content=<a href='/topic/show?id=0c4094e0431' target=_blank style='color:#2F92EE;'>#适应性免疫#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94704, encryptionId=0c4094e0431, topicName=适应性免疫)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1376173, createdName=linagood, createdTime=Tue Mar 30 23:11:22 CST 2021, time=2021-03-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1767768, encodeId=ff501e6776815, content=<a href='/topic/show?id=64f5343e2f' target=_blank style='color:#2F92EE;'>#Biol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3437, encryptionId=64f5343e2f, topicName=Biol)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=446937890434, createdName=12498ebem31暂无昵称, createdTime=Thu Apr 29 17:11:22 CST 2021, time=2021-04-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1919083, encodeId=9f02191908378, content=<a href='/topic/show?id=4f26341994' target=_blank style='color:#2F92EE;'>#Bio#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=19, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3419, encryptionId=4f26341994, topicName=Bio)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12de429, createdName=sunylz, createdTime=Mon Mar 29 19:11:22 CST 2021, time=2021-03-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1857888, encodeId=8ce1185e8880a, content=<a href='/topic/show?id=3f48525849' target=_blank style='color:#2F92EE;'>#CRO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5258, encryptionId=3f48525849, topicName=CRO)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c30265, createdName=jiafufeng@yaho, createdTime=Wed Feb 17 17:11:22 CST 2021, time=2021-02-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1621037, encodeId=74a3162103ec8, content=<a href='/topic/show?id=dccc94e01c9' target=_blank style='color:#2F92EE;'>#适应性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94701, encryptionId=dccc94e01c9, topicName=适应性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b13a20191510, createdName=huhuaidong394, createdTime=Tue Jun 16 09:11:22 CST 2020, time=2020-06-16, status=1, ipAttribution=)]
  6. [GetPortalCommentsPageByObjectIdResponse(id=2084591, encodeId=f6f220845912b, content=<a href='/topic/show?id=61f411e013b' target=_blank style='color:#2F92EE;'>#Micro#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=19, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11701, encryptionId=61f411e013b, topicName=Micro)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d59291, createdName=xjy02, createdTime=Thu Aug 06 22:11:22 CST 2020, time=2020-08-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1814228, encodeId=f6971814228d5, content=<a href='/topic/show?id=0c4094e0431' target=_blank style='color:#2F92EE;'>#适应性免疫#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94704, encryptionId=0c4094e0431, topicName=适应性免疫)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1376173, createdName=linagood, createdTime=Tue Mar 30 23:11:22 CST 2021, time=2021-03-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1767768, encodeId=ff501e6776815, content=<a href='/topic/show?id=64f5343e2f' target=_blank style='color:#2F92EE;'>#Biol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3437, encryptionId=64f5343e2f, topicName=Biol)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=446937890434, createdName=12498ebem31暂无昵称, createdTime=Thu Apr 29 17:11:22 CST 2021, time=2021-04-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1919083, encodeId=9f02191908378, content=<a href='/topic/show?id=4f26341994' target=_blank style='color:#2F92EE;'>#Bio#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=19, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3419, encryptionId=4f26341994, topicName=Bio)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12de429, createdName=sunylz, createdTime=Mon Mar 29 19:11:22 CST 2021, time=2021-03-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1857888, encodeId=8ce1185e8880a, content=<a href='/topic/show?id=3f48525849' target=_blank style='color:#2F92EE;'>#CRO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5258, encryptionId=3f48525849, topicName=CRO)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c30265, createdName=jiafufeng@yaho, createdTime=Wed Feb 17 17:11:22 CST 2021, time=2021-02-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1621037, encodeId=74a3162103ec8, content=<a href='/topic/show?id=dccc94e01c9' target=_blank style='color:#2F92EE;'>#适应性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94701, encryptionId=dccc94e01c9, topicName=适应性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b13a20191510, createdName=huhuaidong394, createdTime=Tue Jun 16 09:11:22 CST 2020, time=2020-06-16, status=1, ipAttribution=)]

相关资讯

李克强:精准做好常态化防控,进一步加强疫苗药物和检测试剂研发工作

6月4日,中共中央政治局常委、国务院总理、中央应对新冠肺炎疫情工作领导小组组长李克强主持召开领导小组会议。

CELL:我国研究人员开发出新冠候选疫苗,并可量产

BBIBP-CorV表现出高效的生产力和良好的遗传稳定性,可用于疫苗生产。这些结果支持在临床试验中进一步评估BBIBP-CorV。

王志刚:中国疫苗研制成功,将作为公共产品向全球提供

国务院新闻办公室于2020年6月7日(星期日)发表《抗击新冠肺炎疫情的中国行动》白皮书,并于当日上午10时举行新闻发布会,请中央宣传部副部长、国务院新闻办公室主任徐麟,科学技术部部长王志刚,国家卫生健

新冠疫苗出来后先为谁接种?还要继续戴口罩吗?

7日,国务院新闻办公室发布《抗击新冠肺炎疫情的中国行动》白皮书。发布会上,相关部门负责人介绍了白皮书有关情况并答记者问。

J Infect Dis:HSV529疫苗可有效且安全用于预防单纯疱疹病毒2感染

单纯疱疹病毒2(HSV2)导致全球有4亿多人感染生殖器疱疹。